Clinical Development of NurOwn®

We have undertaken three clinical trials in ALS to date:

In all three trials, the primary endpoints were the safety and tolerability of a single intramuscular, intrathecal or simultaneous intramuscular and intrathecal administration. Key secondary efficacy endpoints included the rate of change in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) (and in forced vital capacity (FVC) during the post-treatment period compared to a three month pre-treatment run-in period.

View our available results from these studies.